Remove 2024 Remove AFIB Remove Pulmonary
article thumbnail

Cortex Announces RESOLVE-AF Trial Evaluating Electrographic Flow (EGF) Mapping for use in Atrial Fibrillation Ablation

DAIC

Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. AFib is the most common heart rhythm disorder, affecting more than 30 million patients worldwide.

Ablation 104
article thumbnail

Medtronic’s PulseSelect Becomes First FDA-Approved PFA System

CardiacWire

The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. PFA systems use electroporation (short electrical pulses) to achieve pulmonary vein isolation.

AFIB 105
article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

article thumbnail

SHAM-PVI: Pulmonary Vein Isolation vs. Sham Intervention in Patients With Symptomatic AFib

American College of Cardiology

Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.

AFIB 40
article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." In the U.S.,

article thumbnail

Volta Medical Enters into Joint Development Agreement with GE HealthCare to Support Electrophysiologists Treating Atrial Fibrillation

DAIC

Image courtesy: Getty Images christine.book Wed, 07/24/2024 - 09:00 July 24, 2024 — Volta Medical , a health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists, has announced a Joint Development Agreement with GE HealthCare.

article thumbnail

Findings From SUPPRESS-AF and CRABL-HF Shed Light on AFib Treatments

American College of Cardiology

Performing additional catheter ablations targeting diseased myocardium along with the standard approach of pulmonary vein isolation (PVI) to treat persistent atrial fibrillation (AFib) did not reduce the recurrence of AFib at one year, based on findings from the SUPPRESS-AF trial presented at ESC Congress 2024 in London.

AFIB 40